Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer

By Global News Feed

SAN DIEGO, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has appointed Kaitlyn Arsenault, CPA, as Chief Financial Officer. Ms. Arsenault brings over 14 years of experience in accounting, auditing, financial reporting, mergers and acquisitions, as well as business operations in the life science and technology sectors.

See the rest here:
Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer

Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer

By Global News Feed

NEW YORK and SCOTTSDALE, Ariz., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”) focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products, today announces the appointment of Ernest De Paolantonio as Chief Financial Officer, effective September 30, 2021.

See the original post:
Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer

Albireo Recognizes PFIC Awareness Day 2021

By Global News Feed

BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2021, a global effort to support patients and families affected by progressive familial intrahepatic cholestasis (PFIC). Established in 2019, PFIC Awareness Day aims to highlight the impact of this disease on patients and families, and to call for new levels of support, including research, advocacy, education and opportunities to connect and share information.

Read more:
Albireo Recognizes PFIC Awareness Day 2021

Genovac Purchases Third Beacon® Optofluidic System and Expands its Capabilities into Cell Line Development

By Global News Feed

Genovac Becomes the First Contract Research Organization (CRO) to Leverage the Beacon System for Both Antibody Discovery and Cell Line Development Genovac Becomes the First Contract Research Organization (CRO) to Leverage the Beacon System for Both Antibody Discovery and Cell Line Development

Read the original post:
Genovac Purchases Third Beacon® Optofluidic System and Expands its Capabilities into Cell Line Development

Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities

By Global News Feed

LAWRENCEVILLE, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion in its vaccine development program, and the hiring of a veteran clinical trial project manager for its Phase II GEN-1 immunotherapy study in advanced ovarian cancer. These changes all are effective immediately and are as follows:

Link:
Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities

CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

By Global News Feed

MENLO PARK, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 5th Annual NASH Investor Conference, being held virtually on October 12, 2021.

View post:
CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy

By Global News Feed

CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the e-poster presentation of new preclinical data at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy, taking place October 5-6, 2021. The e-poster titled “Expression of an IL-15 Receptor Fusion Protein Enhances the Persistence of TRuC-T Cells” highlights preclinical data on the Company’s proprietary mesothelin-directed T Cell Receptor Fusion Construct (TRuC®) T cells that express IL-15-based enhancements as a strategy for improving T cell persistence. The co-expression of these IL-15 enhancements enriched for naïve and central memory T cells, upregulated the stemness-associated transcription factor TCF-1 and increased TRuC-T cell proliferation upon repeated stimulation with mesothelin-expressing cancer cell lines. In addition, IL-15 promoted the survival of TRuC-T cells in the absence of T cell receptor (TCR) or exogenous cytokine stimulation. In a mesothelioma xenograft mouse model, IL-15 co-expression resulted in a higher number of TRuC-T cells in the tumor and significantly increased their persistence in peripheral blood. The administration of a single dose of IL-15 enhanced TRuC-T cells cleared tumors in all mice and fully protected them from tumor rechallenge.

See the original post:
TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy

Levitee Labs Publishes First Revenue Figures for August 2021

By Global News Feed

VANCOUVER, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Levitee Labs Inc. (the "Company" or "Levitee Labs”) (CSE: LVT), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to publish revenue figures for the month of August 2021. On a consolidated basis, the Company has recorded (unaudited) revenue of $893,863 for the month of August.

See the rest here:
Levitee Labs Publishes First Revenue Figures for August 2021

→←